SCHEMBL4110573

SCHEMBL4110573

Nc1nc(N2CCN(C(=S)NCc3cccc(Cl)c3)CC2)c2nc(-c3ccc(F)cc3)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.47
PDGFRA P16234 1/20 0.47
MAPT P10636 5/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
KDM4E B2RXH2 1/20 0.41
MAP4K4 O95819 1/20 0.39
CDK1 P06493 1/20 0.38
IGF1R P08069 1/20 0.38
FGFR1 P11362 1/20 0.38
BRAF P15056 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113664 0.93 PDGFRB (0.41) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4114415 0.90 PDGFRB (0.47) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4108696 0.90 PDE4A (0.41) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4121099 0.90 PDE4A (0.52) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL4121965 0.90 PDE4A (0.49) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4107922 0.90 PDGFRB (0.47) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4106755 0.89 ALDH1A1 (0.44) PDGFRBPDGFRAMEN1KMT2APDE4A
SCHEMBL4107503 0.87 PDE4A (0.62) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4107542 0.85 PDGFRB (0.46) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL4107667 0.85 PDGFRB (0.45) PDGFRBPDGFRAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-10-22 US disclosed
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-02-05 US disclosed
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP PDGFRB 199/4885PDGFRA 292/4885MAPT 1541/4885
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP PDGFRB 199/4885PDGFRA 292/4885MAPT 1541/4885
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP PDGFRB 199/4885PDGFRA 292/4885MAPT 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.